A randomized phase II trial comparing two doses of pulsed erlotinib prechemotherapy (PEP-C) in patients with stage IIIB or IV non-small cell lung cancer.

Trial Profile

A randomized phase II trial comparing two doses of pulsed erlotinib prechemotherapy (PEP-C) in patients with stage IIIB or IV non-small cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2010

At a glance

  • Drugs Carboplatin; Erlotinib; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Feb 2009 Results published in Journal of Clinical Oncology 27: 264-270, No. 2, 10 Jan 2009
    • 03 Feb 2009 Status changed from active, no longer recruiting to completed.
    • 10 Jan 2009 Staus change from active, no longer recruiting to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top